Lord, Abbett & Co. LLC Incyte Corp Transaction History

Lord, Abbett & Co. LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$73.52 - $88.7 $14.9 Million - $18 Million	-202,676 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$63.56 - $88.17 $12.9 Million - $17.9 Million	202,676 New	202,676 $17.4 Million
Q2 2018 Aug 14, 2018	SELL	$60.85 - $83.98 $2.43 Million - $3.36 Million	-40,004 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$83.06 - $100.98 $807,592 - $981,828	-9,723 Reduced 19.55%	40,004 $3.33 Million
Q4 2017 Feb 14, 2018	SELL	$93.56 - $116.6 $9.69 Million - $12.1 Million	-103,527 Reduced 67.55%	49,727 $4.71 Million
Q3 2017 Nov 14, 2017	SELL	$109.15 - $138.27 $33.2 Million - $42.1 Million	-304,201 Reduced 66.5%	153,254 $17.9 Million
Q2 2017 Aug 14, 2017	BUY	N/A	457,455	457,455 $57.6 Million

657

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.5B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.